Email This Article

Headlines & Perspectives
Survival Data Still Key for Medarex
By Elizabeth Trotta
05/17/08 - 12:13 PM EDT
New data released on melanoma candidate ipilimumab offers no surprises.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,291.26 1,098.51 2,166.90 34.74
Oil *
77.90
UP
44.29
UP
5.50
UP
15.82
DOWN
0.08
10 Yr
3.47%
SPDR Gold
109.60
+0.43%
+0.50%
+0.74%
-0.23%
Data delayed 20 minutes

Brokerage Partners